BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

• BeyondSpring Inc (NASDAQ: BYSI) announced data from a poster presentation at the ESMO Congress 2022, including a new analysis from the Phase 2/3 PROTECTIVE-1 and PROTECTIVE-2 trials of plinabulin.

• Plinabulin, the company's lead asset, is a selective immunomodulating microtubule-binding agent, a potent antigen-presenting cell (APC) inducer being developed as an anticancer agent.

• Related: BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients.

• The data provides evidence of protection of bone marrow granulocyte-monocyte progenitor (GMP) stem cells within 24 hours after chemotherapy based on an evaluation of peripheral immature and mature neutrophil counts.

• The absolute neutrophil count (ANC) with and without plinabulin was comparable at pre-dose C1D1 (p=0.96) but was significantly higher at 24 hours post-chemo dose with plinabulin vs. control.

• At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin, whereas the mean ANC had decreased by 0.55 x 109/L with the control due to the myelosuppressive effect of TAC chemotherapy.

• Price Action: BYSI shares are down 0.47% at $1.52 on the last check Tuesday.

See more from Benzinga

• Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir

• FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss

• Trump Says Putin's Ukraine Invasion Will Result In World War 3: 'Watch What's Going To Happen With China

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.